SUPERNUS PHARMACEUTICALS, INC. 8K

Supernus Pharmaceuticals announced a planned tax‑free stock‑for‑stock merger of equals with Indivior to form Supernus, Inc., a diversified CNS biopharmaceutical leader with pro forma revenues of about $2.2 billion and at least $125 million in expected annual cost synergies, targeted to close in Q4 2026.

On August 3, 2026, Supernus Pharmaceuticals, Inc. filed an investor presentation under Rule 425 and deemed filed under Rule 14a‑12 describing a definitive agreement for a 100% stock‑for‑stock, tax‑free merger of equals with Indivior, under which Supernus shareholders will receive 1.5401 Indivior shares for each Supernus share, Indivior will pay a pre‑closing $1 billion special dividend to its existing shareholders, and the combined CNS‑focused biopharmaceutical company—Supernus, Inc., headquartered in Rockville, Maryland—will have an approximately $2.2 billion pro forma revenue base, at least $125 million in expected annual cost synergies, a balanced post‑closing ownership split (56.5% Indivior / 43.5% Supernus), shared board and leadership structure led by Supernus CEO Jack Khattar, and an anticipated closing in Q4 2026 subject to shareholder and regulatory approvals and other customary conditions.

Filing Facts

CIK

1356576

Ticker

SUPN

Form

8K

Source Type

fda

Accession

0001104659-26-089524

Alert Tier

8